CABALETTA BIO, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
CABALETTA BIO, INC. (CABA) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $50.96 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-13
- CABALETTA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $0.00.
- CABALETTA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $50.96M.
- CABALETTA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $50.00M, a 300.00% increase year-over-year.
- CABALETTA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- CABALETTA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $50.00M, a 1.01% increase from fiscal 2024.
- CABALETTA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $49.50M, a 20.80% decline from fiscal 2023.
- CABALETTA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $62.50M, a 150.00% increase from fiscal 2022.
- CABALETTA BIO, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $25.00M, a 248.92% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $50.96M 10-Q · filed 2026-08-13 | $100.96M derived: sum of 3 quarters · filed 2026-08-13 | $100.96M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $50.96M 10-Q · filed 2026-05-14 | $100.96M derived: sum of 2 quarters · filed 2026-05-14 | $100.96M derived: sum of 3 quarters · filed 2026-05-14 | $100.96M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $50.00M derived: sum of 2 quarters · filed 2026-03-23 | $50.00M derived: sum of 3 quarters · filed 2026-08-13 | $50.00M 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $0.00 10-Q · filed 2025-11-10 | $12.50M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $12.50M derived: sum of 3 quarters · filed 2026-08-13 | $25.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-14 | $12.50M derived: sum of 2 quarters · filed 2026-05-14 | $25.00M derived: sum of 3 quarters · filed 2026-05-14 | $49.50M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $12.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $25.00M derived: sum of 2 quarters · filed 2026-03-23 | $49.50M derived: sum of 3 quarters · filed 2026-03-23 | $49.50M 10-K · filed 2026-03-23 |
| 2024-09-30 | $12.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $37.00M derived: sum of 2 quarters · filed 2025-11-10 | $37.00M 10-Q · filed 2025-11-10 | $74.50M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $24.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $24.50M 10-Q · filed 2025-08-07 | $62.00M derived: sum of 3 quarters · filed 2025-08-07 | $62.00M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | $37.50M derived: sum of 2 quarters · filed 2025-03-31 | $37.50M derived: sum of 3 quarters · filed 2025-03-31 | $37.50M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-12-31 | $37.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $37.50M derived: sum of 2 quarters · filed 2025-03-31 | $37.50M derived: sum of 3 quarters · filed 2025-03-31 | $62.50M 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $25.00M 10-Q · filed 2024-11-14 | $25.00M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $25.00M 10-Q · filed 2024-08-08 | $25.00M derived: sum of 3 quarters · filed 2024-08-08 | $50.00M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $25.00M 10-Q · filed 2024-05-15 | $25.00M derived: sum of 2 quarters · filed 2024-05-15 | $50.00M derived: sum of 3 quarters · filed 2024-05-15 | $50.00M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $25.00M derived: sum of 2 quarters · filed 2024-03-21 | $25.00M derived: sum of 3 quarters · filed 2024-03-21 | $25.00M 10-K · filed 2024-03-21 |
| 2022-09-30 | $25.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $25.00M derived: sum of 2 quarters · filed 2023-11-09 | $25.00M 10-Q · filed 2023-11-09 | $26.00M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $1.00M derived: sum of 3 quarters · filed 2023-08-10 | $3.30M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $1.00M derived: sum of 2 quarters · filed 2023-05-11 | $3.30M derived: sum of 3 quarters · filed 2023-05-11 | $4.71M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $3.30M derived: sum of 2 quarters · filed 2023-03-16 | $4.71M derived: sum of 3 quarters · filed 2023-03-16 | $7.17M 10-K · filed 2023-03-16 |
| 2021-09-30 | $2.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.71M derived: sum of 2 quarters · filed 2022-11-10 | $6.17M 10-Q · filed 2022-11-10 | $8.28M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $3.87M 10-Q · filed 2022-08-11 | $5.98M derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $2.45M 10-Q · filed 2022-05-12 | $4.57M derived: sum of 2 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $3.75M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $1.63M 10-Q · filed 2021-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |